Austrian researchers keep one step ahead of coronavirus mutations

24 February 2021
coronavirus_credit_deposit_photos-_largre

The Austrian Center of Industrial Biotechnology (acib) has published research in Scientific Reports describing less common coronavirus mutations which could be of significance for researchers.

The mutations result in stronger binding to human cell receptors, and the group believes this could result in a potentially higher infection rate.

The S477G variant, which first appeared in Vienna, is now found in eight countries, with more than 27,000 people worldwide having been infected.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology